To validate our results in an independent cohort, and also assess potential differences with non-alpha SARS-CoV-2 viral variants, we applied the three IFNα assays to another cohort of COVID-19 patients (Supplemental Data 2) recruited during a different wave of infection when the delta variant was prominent (December 2020–April 2021). The gene discussed is IFNA2; the disease is infection.